Jack - amatica health
jackamatica.bsky.social
Jack - amatica health
@jackamatica.bsky.social
ME/CFS patient and researcher

Co founder of amatica health

https://amaticahealth.com
We at @amaticahealth will be offering the most extensive patient facing antibody testing ever in 2026, to identify correlations between disease profiles (symptoms, severity, treatment response, etc), so stay tuned for that!
November 28, 2025 at 1:56 PM
Together, these studies point toward antibodies as one possible mechanism in Long COVID, ME/CFS, and related conditions.

Not all patients may fit this pattern, and more research is underway, including planned ME/CFS IgG transfer models.
November 28, 2025 at 1:56 PM
Fibromyalgia research found similar patterns.

IgG from patients transferred pain sensitivity and reduced activity to mice.

This provides further support that antibodies may influence chronic pain and fatigue conditions.
November 28, 2025 at 1:56 PM
This pattern hints that reducing certain antibodies may help some individuals, although larger and controlled trials are needed to confirm this.
November 28, 2025 at 1:56 PM
A clinical immunoadsorption study removed IgG from post-COVID ME/CFS patients.

Many experienced short-term improvements in fatigue, function, pain, and orthostatic symptoms.

Effects faded as IgG levels returned.
November 28, 2025 at 1:56 PM
ME/CFS IgG also changed how healthy immune cells released cytokines.

This suggests that antibodies in these conditions may interfere with immune signalling.
November 28, 2025 at 1:56 PM
In endothelial cells, ME/CFS IgG contributed to mitochondrial fragmentation.

Fab fragments drove most of this effect, while Fc fragments had smaller impacts on cell energy levels.
November 28, 2025 at 1:56 PM
A related ME/CFS study added patient IgG to healthy human cells.

The antibodies disrupted normal cell function, including mitochondrial behaviour and inflammatory signalling.

This may help explain fatigue and immune issues, but more work is needed.
November 28, 2025 at 1:56 PM
These findings suggest that, for some Long COVID patients, certain antibodies may play a role in ongoing symptoms.

The studies are early and based on preprints, so results need further validation.
November 28, 2025 at 1:56 PM
Mice that received IgG from people with neurological symptoms showed pain sensitivity, coordination problems, and signs that resemble small-fiber nerve changes.

Healthy IgG did not produce these effects.
November 28, 2025 at 1:56 PM
In Long COVID, two independent teams purified IgG from patients and injected it into healthy mice.

The mice developed increased pain sensitivity, reduced activity, or balance issues depending on which patient subgroup the antibodies came from.
November 28, 2025 at 1:56 PM
November 25, 2025 at 3:32 PM
The results support testing GNA lectin based filtration, such as the Hemopurifier, in Long COVID.

A clinical trial is needed to see if removing these EVs reduces symptoms.
November 25, 2025 at 3:32 PM
The study did not test whether the mannose rich EVs carry viral proteins, autoantibodies, or reactivated viruses like EBV.

These will need to be investigated in future work.
November 25, 2025 at 3:32 PM
The study has limits.

The sample size was small.
It examined only one time point.
The miRNA panel covers a fixed list of miRNAs.
Pathway effects were predicted rather than measured directly.
November 25, 2025 at 3:32 PM
The results suggest that filtering mannose rich EVs may help rebalance immune and repair signals in Long COVID.

This is only a prediction and needs clinical testing.
November 25, 2025 at 3:32 PM
Some inflammatory pathways like NF kB, MAPK, and TNF alpha were predicted to rise.

This may help certain Long COVID patients because some subgroups have unusually low immune responses that need restoring.
November 25, 2025 at 3:32 PM
Other pathways, such as Estrogen, VEGF, EGFR, and PI3K, were predicted to increase.

These pathways can support blood vessel repair, tissue recovery, and nitric oxide production, which influences blood flow.
November 25, 2025 at 3:32 PM
Removing these miRNAs was predicted to lower activity in the JAK STAT pathway.

This pathway is often kept active by interferons, which are immune signals. Overactive interferon signaling has been suggested as a driver of persistent symptoms.
November 25, 2025 at 3:32 PM
The 7 miRNAs each regulate specific genes. In total, they influence 32 known gene targets.

The team used these known interactions to predict how removing the miRNAs might shift biological pathways.
November 25, 2025 at 3:32 PM
Out of 827 miRNAs measured, 358 were detected in meaningful amounts. After correction for many tests, 7 miRNAs were significantly reduced by GNA treatment.

This means these 7 miRNAs were likely carried by mannose rich EVs.
November 25, 2025 at 3:32 PM
The team also studied miRNA.

These are short RNA sequences carried by EVs that can change how genes behave.

They measured which miRNAs were removed from plasma after GNA resin treatment.
November 25, 2025 at 3:32 PM
Recovered people did not show this pattern.

Their EVs did not correlate with removal by GNA resin.

This suggests that mannose related changes are specific to Long COVID.
November 25, 2025 at 3:32 PM
Small EVs from Long COVID samples were removed more by the GNA resin than small EVs from recovered people.

The more mannose positive EVs someone had, the more EVs the resin removed.
November 25, 2025 at 3:32 PM